UNIGE document Scientific Article
previous document  unige:73681  next document
add to browser collection
Title

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

Authors
Marcelin, Anne-Geneviève
Delaugerre, Constance
Beaudoux, Céline
Descamps, Diane
Morand-Joubert, Laurence
Amiel, Corinne
show hidden authors show all authors [1 - 24]
Published in International Journal of Antimicrobial Agents. 2013, vol. 42, no. 1, p. 42-7
Abstract This study aimed to identify factors associated with virological response (VR) to raltegravir (RAL)-containing regimens in 468 treatment-experienced but integrase inhibitor-naive HIV-1 patients receiving a RAL-containing regimen. VR was defined at Month 6 (M6) as HIV-1 RNA viral load (VL) <50 copies/mL. The impacts on VR of baseline integrase mutations, VL, CD4 count, genotypic sensitivity score for nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the number of new antiretrovirals used for the first time associated with RAL were investigated. For patients with VL >50 copies/mL at M6, integrase mutations selected were characterised. Median baseline VL was 4.2 log(10)copies/mL (IQR 3.3-4.9 log(10) copies/mL) and CD4 count was 219 cells/mm(3) (IQR 96-368 cells/mm(3)). At M6, 71% of patients were responders. In multivariate analysis, baseline VL and CD4 count and ≥ 2 new antiretrovirals among darunavir, etravirine, maraviroc and enfuvirtide were associated with VR to RAL. Neither HIV-1 subtype nor baseline integrase polymorphisms were associated with VR to RAL. Among 63 failing patients at M6, selection of ≥ 1 change in the integrase gene was observed in 49 (77.8%), and 27/63 (42.9%) were considered as RAL-associated resistance mutations. Factors independently associated with the occurrence of ≥ 1 RAL-associated resistance mutation were VL at failure >3 log(10) and having no new drugs associated with RAL. RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR.
Keywords Anti-HIV Agents/therapeutic useAntiretroviral Therapy, Highly Active/methodsCD4 Lymphocyte CountCohort StudiesDrug Resistance, ViralFemaleHIV Infections/drug therapy/virologyHIV-1/genetics/isolation & purificationHumansMaleMutation, MissensePyrrolidinones/therapeutic useRNA, Viral/bloodTreatment FailureViral Load
Identifiers
PMID: 23562640
Full text
Article (Published version) (494 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Laurent Kaiser (virologie clinique) (668)
Citation
(ISO format)
MARCELIN, Anne-Geneviève et al. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. In: International Journal of Antimicrobial Agents, 2013, vol. 42, n° 1, p. 42-7. https://archive-ouverte.unige.ch/unige:73681

119 hits

0 download

Update

Deposited on : 2015-06-25

Export document
Format :
Citation style :